Skip to main content
Clinical Trials/NCT06397352
NCT06397352
Completed
N/A

Effects of Buzzy® and ShotBlocker® on Pain, Anxiety and Satisfaction During the Administration of Tetanus-Diphtheria Vaccine to School-Aged Children: A Randomized Controlled Trial

Mehmet Akif Ersoy University1 site in 1 country138 target enrollmentNovember 1, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Pain
Sponsor
Mehmet Akif Ersoy University
Enrollment
138
Locations
1
Primary Endpoint
Visual Analog Scale (VAS)
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The aim of this study was to detect and compare the effects of ShotBlocker® and Buzzy® methods on pain, anxiety, and satisfaction during the administration of Tetanus-Diphtheria vaccine to school-aged children. This study was an experimental randomized controlled trial. The sample was included 138 children in a family health centers aged 13 years who underwent Tetanus-Diphtheria vaccine. The participants were randomly assigned to ShotBlocker®, Buzzy®, and control groups. Each group included 46 children, of whom 23 were female and 23 were male. The State-Trait Anxiety Inventory and Visual Analog Scale were used to collect the data.

Detailed Description

This research aims to determine effects of Buzzy® and ShotBlocker® on pain and anxiety during the administration of tetanus-diphtheria vaccine to school-aged children. The following hypotheses were determined for the present study. Hypothesis 1. ShotBlocker® is effective in reducing pain and anxiety of children and increasing satisfaction during Tetanus-Diphtheria vaccine injection. Hypothesis 2. Buzzy® is effective in reducing pain and anxiety of children and increasing satisfaction during Tetanus-Diphtheria vaccine injection. Hypothesis 3. Buzzy® is more effective than ShotBlocker in reducing pain and anxiety of children and increasing satisfaction during Tetanus-Diphtheria vaccine injection. This prospective, randomised controlled study was conducted in one family health centers of Manisa, Turkey, between November 2021- August 2023. A parallel trial design was used describing, shotblocker, buzzy, and control group as the third arm. This study was guided by the Consolidated Standards of Reporting Trials (CONSORT) checklist. This study was conducted in one family health centers with the same nurse. Children aged 13 years who underwent tetanus- Diftevaccine injection were eligible to participate in the study. The inclusion criteria were being 13 years and being conscious (with the ability to communicate). The exclusion criteria were having a physical and psychological condition; taking any analgesics, sedatives, or anticonvulsants in the past 24 hours; having chronic or life-threatening disease; and refusing the shotblocker or buzzy intervention during vaccine injection. The sample size for the research was determined using G\*power 3.0.8 software, and power analysis was conducted. With a 5% error rate, 80% power, and a medium effect size of 0.25 for the 3 groups with 2 repeated factors, it was calculated that 46 children should be taken for each group (Ellis, 2010). The study sample composed of 138 children. Childrens presenting for tetanus vaccine injection and fulfilling the inclusion criteria were assigned into three groups: Shotblocker®, Buzzy® and control groups (exposed to the conventional injection technique). So that effects of gender could be controlled, the childrens were first categorized according to their genders and then assigned into the three groups through block randomization. To ensure randomization and minimize all possible negative effects, the words shotblocker, buzzy and control, representing the three groups, were written on papers of the same color and shape and placed in a pink and a blue box. During the routine vaccination of children, which group would be included was determined by a lottery drawn by the child, just before the procedure started. The girls were asked to draw a paper from the pink box and boys from the blue box. This allowed keeping the effect of gender under control. Each group included 46 children, of whom 23 were female and 23 were male.

Registry
clinicaltrials.gov
Start Date
November 1, 2021
End Date
September 1, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Mehmet Akif Ersoy University
Responsible Party
Principal Investigator
Principal Investigator

Hatice ERDEM ÖNDER

Research Assistant Dr.

Mehmet Akif Ersoy University

Eligibility Criteria

Inclusion Criteria

  • being conscious (with the ability to communicate)

Exclusion Criteria

  • having a physical and psychological condition
  • taking any analgesics, sedatives, or anticonvulsants in the past 24 hours
  • having chronic or life-threatening disease
  • refusing the shotblocker or buzzy intervention during vaccine injection.

Outcomes

Primary Outcomes

Visual Analog Scale (VAS)

Time Frame: Visual Analog Scale were completed immediately after the vaccination.

This scale consists of a 10-cm line (0-10 cm or 0-100 mm). The 0-line on the scale indicates "no pain," and the 10-line indicates "unbearable pain." The child is asked to mark the place that expresses the degree of pain. The distance from the point marked by the child to the 0 line is measured to determine the degree of pain. In children aged 8 and above, the Visual Analog Scale (VAS) is considered the most reliable method.

Secondary Outcomes

  • State-Trait Anxiety Inventory (STAI)(State-Trait Anxiety Inventory (STAI) were completed immediately after the vaccination)
  • Satisfaction level(Satisfaction were completed immediately after the vaccination)

Study Sites (1)

Loading locations...

Similar Trials

Effects of Buzzy® and ShotBlocker® on... | Clinical Trial